Mayne Pharma shares lift as its contraceptive pill is added to PBS
Make us a preferred source
Make us a preferred source on Google
The news: Mayne Pharma shares lifted in morning trade after the drug company announced that its flagship birth control pill NEXTSTELLIS will be listed on Australia’s pharmaceutical benefits scheme (PBS) from 1 October 2025.
The numbers: At 10:15am AEST, shares in Mayne Pharma were up 1.7% to $5.25.
The company said that without a PBS listing, NEXTSTELLIS would cost more than $328 per year.
Following the listing, three months worth of supply can be accessed for $31.60 with the price to fall to $25 on 1 January 2026. The three month price is $7.70 for concession card holders.
The context: NEXTSTELLIS was approved by the Therapeutic Goods Administration in November 2021 as the first and only contraceptive pill containing estetrol — estrogen derived from a plant source — and a progestin called drospirenone.
What they said: “We are pleased with the PBS listing of NEXTSTELLIS,” Mayne Pharma CEO and managing director Shawn O’Brien said.
“The expansion of contraceptive options available on the PBS in Australia aligns with Mayne Pharma’s commitment to provide better, safe and more accessible medicines.”
The source: ASX
